Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MD

January 16th 2013

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.

Dr. Oh on Combination Therapy in Prostate Cancer

January 8th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

Sequencing of Novel Prostate Cancer Agents Is a Work in Progress

December 26th 2012

Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.

Frank delaRama on Patient Education in Prostate Cancer

December 19th 2012

Frank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.

Helping Prostate Cancer Patients to Make Informed Treatment Decisions

December 19th 2012

Information is key, as patients with early-stage prostate cancer typically choose among three standard treatment options: watchful waiting/active surveillance, surgery, and radiation.

The USPSTF Prostate Cancer Screening Recommendations: Urologists Discuss Its Message and Impact on Their Practices

December 12th 2012

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.

Dr. Shore on Current Clinical Trial Challenges in CRPC

December 12th 2012

Effective Management of Prostate Cancer Conclusion

December 12th 2012

Revenue Opportunities and GPOs for Urology Groups

December 12th 2012

Reimbursement Issues in Prostate Cancer, Part II

December 12th 2012

Reimbursement Issues in Prostate Cancer, Part I

December 12th 2012

Dr. Shore on the Management of Patients with CRPC

December 12th 2012

Dr. Shore Discusses Therapy Combination in CRPC

December 12th 2012

Management of Patients with Advanced Prostate Cancer

December 12th 2012

Dr. Shore Reviews Emerging Therapies in Prostate Cancer

December 12th 2012

Emerging Therapies in Prostate Cancer

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part II

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part I

December 12th 2012

NCCN Guidelines for Advanced Prostate Cancer

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part II

December 12th 2012